The destabilization of IL-2 mRNA by a premature stop codon and its differential stabilization by trans-acting inhibitors of protein synthesis do not support a role for active translation in mRNA stability.
To investigate the role that translation plays in the stabilization of the IL-2 mRNA, we inhibited protein synthesis in both cis and trans. To block translation in trans, we utilized the inhibitors puromycin (PUR) and cycloheximide (CHX), which differentially effect polysome structure. We found that CHX enhances the stability of IL-2 mRNA in cells stimulated with anti-TCR Ab alone, but it inhibits CD28-induced message stabilization in costimulated cells. In contrast, PUR had a minimal effect on IL-2 mRNA stability in either the presence or absence of costimulation. The differential effects of these two inhibitors suggest that: 1) CHX is unlikely to stabilize the IL-2 mRNA by inhibiting the expression of a labile RNase; 2) CD28-mediated IL-2 mRNA stabilization does not require translation; and 3) IL-2 mRNA decay is not coupled to translation. To block translation in cis, we generated sequence-tagged IL-2 genomic reporters that contain a premature termination codon (PTC). In both the presence and absence of costimulation, these PTC-containing mRNAs exhibit drastically diminished stability. Interestingly, the addition of CHX but not PUR completely restored CD28-mediated stabilization, suggesting that CHX can block the enhanced decay induced by a PTC. Finally, CHX was able to superinduce IL-2 mRNA levels in anti-TCR Ab-stimulated cells but not in CD28-costimulated cells, suggesting that CHX may also act by other mechanisms.
Ragheb
J A
JA
Laboratory of Cellular and Molecular Immunology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA. jr5Ob@nih.gov
Deen
M
M
Schwartz
R H
RH
D000818:Animals; D018106:CD28 Antigens / Q000502:physiology; D002478:Cells, Cultured; D018388:Codon, Terminator / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D003513:Cycloheximide / Q000494:pharmacology; D017930:Genes, Reporter / Q000276:immunology; D007376:Interleukin-2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D051379:Mice; D018716:Molecular Mimicry; D010443:Peptide Chain Termination, Translational / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D014176:Protein Biosynthesis / Q000187:drug effects* / Q000276:immunology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D011691:Puromycin / Q000494:pharmacology; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism*; D016324:Sequence Tagged Sites; D015534:Trans-Activators / Q000494:pharmacology*
D018106:CD28 Antigens; D018388:Codon, Terminator; D007376:Interleukin-2; D011500:Protein Synthesis Inhibitors; D012333:RNA, Messenger; D015534:Trans-Activators; D011691:Puromycin; D003513:Cycloheximide